Acute dilatory and negative inotropic effects of homocysteine are inhibited by an adenosine blocker

Clinical and Experimental Pharmacology and Physiology

Volumn 33, Issue 4, 2006, Pages 340-344

  Kennedy, Richard H ^a,c   Owings, Richard ^a   Joseph, Jacob ^a   Melchert, Russell B ^a   Hauer Jensen, Martin ^b   Boerma, Marjan ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

8 (p sulfophenyl) theophylline (SPT); Atropine; Contractility; Langendorff perfused heart; Rat

Indexed keywords

8 (4 SULFOPHENYL)THEOPHYLLINE; ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; AMINO ACID; ATROPINE; HOMOCYSTEINE; MUSCARINIC RECEPTOR;

ACUTE TOXICITY; ANIMAL TISSUE; ARTERY TONE; ARTICLE; CARDIOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY PRESSURE; DRUG EFFECT; DRUG SELECTIVITY; ELECTROSTIMULATION; HEART FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART PACING; HEART PERFUSION; INOTROPISM; ISOLATED HEART; MALE; MEDIATOR; NONHUMAN; RAT; SYSTOLE; VASCULAR ENDOTHELIUM;

ACETYLCHOLINE; ADENOSINE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATROPINE; CALCIUM CHANNEL BLOCKERS; CORONARY CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; HOMOCYSTEINE; MALE; MUSCLE CONTRACTION; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; NIFEDIPINE; RATS; RATS, SPRAGUE-DAWLEY; THEOPHYLLINE; VASODILATION; VASODILATOR AGENTS;

EID: 33645020697     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2006.04372.x     Document Type: Article

References (28)

1. Boushey CJ Beresford SA Omenn GS Motulsky AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intake JAMA 1995 274 1049 57
2. McCully KS Vascular pathology of hyperhomocysteinemia: Implications for the development of arteriosclerosis AmJPathol 1969 56 111 28
3. Nygard O Vollset SE Refsum H Brattstrom L Ueland PM Total homocysteine and cardiovascular disease JInternMed 1999 246 425 54
4. Nygard O Nordrehaug JE Refsum H Ueland PM Farstad M Vollset SE Plasma homocysteine levels and mortality in patients with coronary artery disease NEnglJMed 1997 337 230 6
5. Schnyder G Orf M Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels NEnglJMed 2001 345 1593 600
6. Blacher J Demuth K Guerin AP et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease JNephrol 1999 12 248 55
7. Vasan RS Beiser A D'Agostino RB et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction JAMA 2003 289 1251 7
8. Joseph J Joseph L Shekhawat NS et al. Hyperhomocysteinemia leads to pathologic ventricular hypertrophy in normotensive rats AmJPhysiol 2003 285 H679 H686
9. Joseph J Washington A Joseph L et al. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats AmJPhysiol 2002 283 H2567 74
10. Kennedy RH Owings R Shekhawat N Joseph J Acute negative inotropic effects of homocysteine are mediated via the endothelium AmJPhysiol 2004 287 H812 H817
11. Upchurch GR Welch GN Fabian AJ et al. Homocyst(e) ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase JBiolChem 1997 272 17012 17
12. Stühlinger MC Tsao PS Her J-H Kimoto M Balint RF Cooke JP Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine Circulation 2001 104 2569 75
13. 3H] phenylxanthine ProcNatl AcadSci 1980 77 5547 51
14. Belardinelli L Linden J Berne RM The cardiac effects of adenosine ProgCardiovascDis 1989 32 73 97
15. Loscalzo J The oxidant stress of hyperhomocysteinemia JClinInvest 1996 98 5 7
16. Stamler JS Osborne JA Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen JClinInvest 1993 91 308 18
17. Cipolla MJ Williamson WK Nehler ML Taylor LM The effect of elevated homocysteine levels on adrenergic vasoconstriction of human resistance arteries: The role of the endothelium and reactive oxygen species JVascSurg 2000 31 751 9
18. Tasatargil A Sadan G Golbasi I Karasu E Turkay C Effects fo short-term exposure to homocysteine on vascular responsiveness of human internal mammary artery JCardiovascPharmacol 2004 43 692 7
19. i and constrictor responses of isolated arterioles JCardiovascPharmacol 2001 37 705 12
20. Olanrewaju HA Mustafa SJ Adenosine A(2A) and A(2B) receptors mediated nitric oxide production in coronary artery endothelial cells GenPharmacol 2000 35 171 7
21. Ray CJ Marshall JM Measurement of nitric oxide release evoked by systemic hypoxia and adenosine from rat skeletal muscle in vivo JPhysiol Physiology in press as 10.1113/jphysiol.2005.094854
22. Wang S Wright G Harrah J et al. Short-term exposure to homocysteine depresses rat aortic contractility by an endothelium-dependent mechanism CanJPhysiolPharmacol 1999 78 500 6
23. Ungvari Z Csiszar A Bagi Z Koller A Impaired nitric oxide-mediated flow-induced coronary dilation in hyperhomocysteinemia: Morphological and functional evidence for increased peroxynitrite formation AmJPathol 2002 161 145 53
24. Quere I Hillaire-Buys D Brunschwig C et al. Effects of homocysteine on acetylcholine- and adenosine-induced vasodilation of pancreatic vascular bed in rats BrJPharmacol 1997 122 351 7
25. Mujumdar VS Hayden MR Tyagi SC Homocysteine induces calcium second messenger in vascular smooth muscle cells JCellPhysiol 2000 183 28 36
26. Chen Y-F Li P-L Zou A-P Effect of hyperhomocysteinemia on plasma and tissue adenosine levels and renal function Circulation 2002 106 1275 81
27. Riksen NP Rongen GA Blom HJ Russel FGM Boers GHJ Smits P Potential role for adenosine in the pathognesis of the vascular complications of hyperhomocysteinemia CardiovascRes 2003 59 271 6
28. Nees S Herzog V Becker BF Bock M DesRosiers C Gerlach E The coronary endothelium: A highly active metabolic barrier for adenosine Basic ResCardiol 1985 80 515 29